TROG Cancer Research
Members Login   CQMS Login

Closed breast trials

Trials closed to recruitment

TROG 12.02 (PET LABRADOR) - the purpose of this study is to investigate whether women with LABC can have breast conservation surgery instead of mastecomy with good outcomes and to work out if MRI and PET-CT are better at seeing how breast cancer responds than mammogram, ultrasound and physical examination by doctors.

Primary sponsor: TROG

TROG 11.01 (SUPREMO) - the purpose of this study was to help researchers decide whether radiotherapy was helpful for women with 'intermediate risk' operable breast cancer following mastectomy.

Primary sponsor: UK Medical Research Council (MRC).
Collaborating groups: TROG; Breast International Group (BIG); Scottish Cancer Trials Group; European Organisation for Research & Treatment of Cancer (EORTC)

TROG 10.02 (RAPID) - this study looked at partial breast irradiation compared to whole breast irradiation to see if it was effective at preventing breast cancer recurrence. The study also investigated if the side-effects were different, if it was more convenient and if it had different effects on the quality of life of women receiving radiation after breast conserving surgery.

Primary sponsor: Ontario Clinical Oncology Group (OCOG)
Collaborating groups: TROG

TROG 08.06 (STARS) - this study compares the effectiveness of treatment with the drug anastrozole before and during adjuvant radiotherapy to anastrozole therapy delayed until after radiotherapy for women who have had a mastectomy or lumpectomy for breast cancer.

Primary sponsor: TROG

TROG 07.01 (DCIS) - In this trial, researchers aimed to determine whether an additional dose of radiation called a boost, given to the part of the breast that had DCIS (Ductal Carcinoma In-Situ) within it was of benefit to the patients. The overall objectives of this trial were to improve the outcome of women with DCIS treated with breast conserving therapy and to individualise treatment selection to achieve long term disease control with minimal side effects.

Primary sponsor: TROG
Collaborating groups: Breast International Group (BIG 3-07); Australia and New Zealand Breast Cancer Trials Group (ANZBCTG); Canadian Cancer Trials Group (CCTG); European Organisation for Research and Treatment of Cancer (EORTC); Scottish Cancer Trials Breast Group (SCTBG); All-Ireland Cooperative Oncology Research Group (ICORG); International Breast Cancer Study Group (IBCSG)

TROG 06.02 - this was a TROG multicentre feasibility study of Accelerated Partial Breast Irradiation (APBI) using 3D conformal radiotherapy in selected women with node-negative breast cancer, and treated by breast conserving surgery.

Primary sponsor: TROG

TROG 03.05 (MA20) - this trial studied radiation therapy to the breast alone, to see how well it worked, compared to radiation therapy to the breast plus surrounding tissue in treating women who had undergone surgery for early-stage invasive breast cancer.

Primary sponsor: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
Collaborating groups: TROG; National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); North Central Cancer Treatment Group (NCCTG); Radiation Therapy Oncology Group (RTOG); Southwest Oncology Group (SWOG)

Trials closed to follow up

TROG 14.04 (HART) - the aim of the HART trial is to implement the Deep Inhalation Breath Hold (DIBH) technique in Australian treatment centres for patients with left-sided breast cancer, to determine whether the technique can reduce radiation to the heart.

Primary sponsor: TROG
Collaborative Group: Breast Cancer Trials 

Completed trials

TROG 89.02 - Simultaneous Adjuvant Radiation and CMF Chemotherapy Following Surgery for Breast Cancer

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.